Masayuki Fukata

Dr. Masayuki Fukata


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2009 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
MFMasayuki Fukata
Masayuki Fukata
MAMaria T Abreu
Maria T Abreu

28 November 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
JSJohn Sotolongo
John Sotolongo
CECecilia España
Cecilia España
AEAndrea Echeverry
Andrea Echeverry
DSDavid Siefker
David Siefker
NANorman Altman
Norman Altman
MFMasayuki Fukata
Masayuki Fukata
Toll-like receptor 4 (TLR4), which signals through the adapter molecules myeloid differentiation factor 88 (MyD88) and toll/interleukin 1 receptor domain-containing adapter inducing IFN-β (TRIF), is required for protection against Gram-negative bacteria. TRIF is known to be important in TLR3-mediated antiviral signaling, but the role of TRIF signaling against Gram-negative enteropathogens is currently unknown. We show that TRIF signaling is indispensable for establishing innate protective immunity against Gram-negative Yersinia enterocolitica. Infection of wild-type mice rapidly induced both IFN-β and IFN-γ in the mesenteric lymph nodes. In contrast, TRIF-deficient mice were defective in these IFN responses and showed impaired phagocytosis in regional macrophages, resulting in greater bacterial dissemination and mortality. TRIF signaling may be universally important for protection against Gram-negative pathogens, as TRIF-deficient macrophages were also impaired in killing both Salmonella and Escherichia coli in vitro. The mechanism of TRIF-mediated protective immunity appears to be orchestrated by macrophage-induced IFN-β and NK cell production of IFN-γ. Sequential induction of IFN-β and IFN-γ leads to amplification of macrophage bactericidal activity sufficient to eliminate the invading pathogens at the intestinal interface. Our results demonstrate a previously unknown role of TRIF in host resistance to Gram-negative enteropathogens, which may lead to effective strategies for combating enteric infections.

16 July 2010 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YHYasmin Hernandez
Yasmin Hernandez
JSJohn Sotolongo
John Sotolongo
KBKeith Breglio
Keith Breglio
DCDaisy Conduah
Daisy Conduah
ACAnli Chen
Anli Chen
MFMasayuki Fukata
Masayuki Fukata
Background: We have previously found that TLR4-deficient (TLR4-/-) mice demonstrate decreased expression of mucosal PGE2and are protected against colitis-associated neoplasia. However, it is still unclear whether PGE2is the central factor downstream of TLR4 signaling that promotes intestinal tumorigenesis. To further elucidate critical downstream pathways involving TLR4-mediated intestinal tumorigenesis, we examined the effects of exogenously administered PGE2in TLR4-/- mice to see if PGE2bypasses the protection from colitis-associated tumorigenesis.Method: Mouse colitis-associated neoplasia was induced by azoxymethane (AOM) injection followed by two cycles of dextran sodium sulfate (DSS) treatment. Two different doses of PGE2(high dose group, 200 μg, n = 8; and low dose group, 100 μg, n = 6) were administered daily during recovery period of colitis by gavage feeding. Another group was given PGE2during DSS treatment (200 μg, n = 5). Inflammation and dysplasia were assessed histologically. Mucosal Cox-2 and amphiregulin (AR) expression, prostanoid synthesis, and EGFR activation were analyzed.Results: In control mice treated with PBS, the average number of tumors was greater in WT mice (n = 13) than in TLR4-/- mice (n = 7). High dose but not low dose PGE2treatment caused an increase in epithelial proliferation. 28.6% of PBS-treated TLR4-/- mice developed dysplasia (tumors/animal: 0.4 ± 0.2). By contrast, 75.0% (tumors/animal: 1.5 ± 1.2, P < 0.05) of the high dose group and 33.3% (tumors/animal: 0.3 ± 0.5) of the low dose group developed dysplasia in TLR4-/- mice. Tumor size was also increased by high dose PGE2treatment. Endogenous prostanoid synthesis was differentially affected by PGE2treatment during acute and recovery phases of colitis. Exogenous administration of PGE2increased colitis-associated tumorigenesis but this only occurred during the recovery phase. Lastly, PGE2treatment increased mucosal expression of AR and Cox-2, thus inducing EGFR activation and forming a positive feedback mechanism to amplify mucosal Cox-2.Conclusions: These results highlight the importance of PGE2as a central downstream molecule involving TLR4-mediated intestinal tumorigenesis.

9 April 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
YTYasuhiro Takagi
Yasuhiro Takagi
TSToshiyuki Sato
Toshiyuki Sato
TNTakanori Nishiguchi
Takanori Nishiguchi
ANAkira Nogami
Akira Nogami
MIMasataka Igeta
Masataka Igeta
Shinichiro ShinzakiShinichiro Shinzaki
Shinichiro Shinzaki
Background: In randomised controlled trials, mirikizumab achieved clinical remission and improved outcomes of patients with moderate to severe ulcerative colitis (UC). However, there is currently no real‐world evidence for mirikizumab.Aim: To evaluate the real‐world effectiveness and safety of mirikizumab.Methods: In a retrospective cohort study among three facilities, we included patients with UC who first received mirikizumab between June 2023 and April 2024. The primary outcome was the change in the partial Mayo score (PMS) from week 0 to 12. Secondary outcomes included changes in serum C‐reactive protein (CRP) and leucine‐rich α2‐glycoprotein (LRG) levels from week 0 to 12; clinical remission rate (PMS < 2 with rectal bleeding subscore of 0), CRP remission rate (< 3.0 mg/L), and LRG remission rate (< 12.7 μg/mL) at week 12; and adverse events during induction therapy.Results: We included 52 patients. Median (interquartile range) PMS decreased from week 0 to 12 (5 [3–6] to 2 [0–3], p < 0.001). CRP and LRG levels also decreased (CRP: 3.8 [0.9–7.3] to 1.8 [0.5–4.0] mg/L, p = 0.015; LRG: 20.1 [16.3–23.2] to 15.9 [12.8–23.2] μg/mL, p = 0.014). Rates of clinical remission, CRP remission, and LRG remission at week 12 were 44.2%, 67.3%, and 27.3%, respectively. There were no adverse events leading to permanent discontinuation of mirikizumab or death.Conclusion: This real‐world study demonstrated the short‐term effectiveness and safety of mirikizumab in patients with UC.

1 January 2013 in Microbes and Infection
Verified
Journal Article
Closed access
JHJinhee Hyun
Jinhee Hyun
SKSaravana Kanagavelu
Saravana Kanagavelu
MFMasayuki Fukata
Masayuki Fukata

12 January 2016 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
JRJose Ruiz
Jose Ruiz
SKSaravana Kanagavelu
Saravana Kanagavelu
CFClaudia Flores
Claudia Flores
LRLaura Romero
Laura Romero
RRReldy Riveron
Reldy Riveron
MFMasayuki Fukata
Masayuki Fukata
Recognition of Gram-negative bacteria by toll-like receptor (TLR)4 induces MyD88 and TRIF mediated responses. We have shown that TRIF-dependent responses play an important role in intestinal defense against Gram-negative enteropathogens. In the current study, we examined underlying mechanisms of how systemic TRIF activation enhances intestinal immune defense against Gram-negative bacteria. First we confirmed that the protective effect of poly I:C against enteric infection of mice with Yersinia enterocolitica was dependent on TLR3-mediated TRIF signaling by using TLR3-deficient mice. This protection was unique in TRIF-dependent TLR signaling because systemic stimulation of mice with agonists for TLR2 (Pam3CSK4) or TLR5 (flagellin) did not reduce mortality on Y. enterocolitica infection. Systemic administration of poly I:C mobilized CD11c+, F4/80+, and Gr-1hi cells from lamina propria and activated NK cells in the mesenteric lymph nodes (MLN) within 24 hours. This innate immune cell rearrangement was type I IFN dependent and mediated through upregulation of TLR4 followed by CCR7 expression in these innate immune cells found in the intestinal mucosa. Poly I:C induced IFN-γ expression by NK cells in the MLN, which was mediated through type I IFNs and IL-12p40 from antigen presenting cells and consequent activation of STAT1 and STAT4 in NK cells. This formation of innate immunity significantly contributed to the elimination of bacteria in the MLN. Our results demonstrated an innate immune network in the intestine that can be established by systemic stimulation of TRIF, which provides a strong host defense against Gram-negative pathogens. The mechanism underlying TRIF-mediated protective immunity may be useful to develop novel therapies for enteric bacterial infection.